Biotechnology Healthcare - June 2008 - (Page 4) Biotechnology Healthcare MAY/JUNE 2008 FEATURE ARTICLES COST MANAGEMENT EMPLOYERS THE IMPACT OF BIOLOGICS ON HEALTH, BUSINESS, AND BENEFITS www.biotechnologyhealthcare.com They Influence Biologics Coverage: a Day in the Life 42 In a perfect world, payers would hire decision makers with a combination of attributes: a scientific understanding of biologics, the ability to get along with physicians, and managed care smarts. Meet SelectHealth’s biologics go-to team. Benefit Designs That Keep Workers on the Job ..52 Pitney Bowes led the way. Now, more and more forward-thinking employers have bought into the idea: Make medications that help to keep workers productive available at little or no cost to the employee. CLINICAL The Private Sector Responds to MRSA 57 The market for effective infection-control interventions is growing. Products that merge information technology with biotechnology can improve quality of care, reduce unnecessary suffering, and eliminate waste of resources. FOCUS: ONCOLOGY AT A GLANCE: Solid Tumors 20 Prevalence of disease, economics of care, and implications for payers, as told in charts. COVER STORY Making Sense of Cancer Trial Endpoints 22 The terminology used in clinical trials means something to researchers and trial sponsors, but what does it mean for you? More importantly, how should you use it to evaluate a therapy or to make coverage decisions? DIAGNOSTICS Putting Molecular Tests to the Test 36 Controversy about the reliability of genetic tests to predict treatment response raises the question: What should you look for to know whether a test has value? The answer may lie in the same principles that guide drug development. DEPARTMENTS Openers 2 Welcome to our new look and focus, and to the era of the digital edition. Editorial 6 We hear what you want, says David B. Nash, MD, MBA. DrugTrack 7 Approvals and other FDA actions, clinical research, and major conference coverage. Personalized Medicine 17 It’s a term that means something different to almost everyone. So, what the devil is it? Editorial Index 62 BIOTECHNOLOGY HEALTHCARE’S 2007 index. Call for Papers 64 Trends 65 When good drugs go 4th tier. BIOTECHNOLOGY HEALTHCARE (ISSN 1554-169x) is published bimonthly by BioCommunications LLC, 780 Township Line Road, Yardley, PA 19067. This is Volume 5, Number 1. Standard postage paid at Morrisville, Pa., and at additional mailing offices. Price: $18 per copy, $95 per year in the United States; $120 per year elsewhere. Phone: (267) 685-2788; fax (267) 6852966; paid subscription inquiries (267) 685-2789. Letters to the editor are accepted for publication consideration at the above address. Copyright 2008, BioCommunications LLC. INDEXED BY CINAHL AND INTERNATIONAL PHARMACEUTICAL ABSTRACTS COVER: JOHN STILL/GETTY IMAGES http://www.biotechnologyhealthcare.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.